In particular, we may anticipate that ANXA2 blocking strategies might be adequate in NPC and OSCC to specifically target its oncopromoter role, but not in other HNSCC subtypes, such as laryngeal and pharyngeal carcinomas, where ANXA2 expression is downregulated and oncosuppressive. The gene discussed is ANXA2; the disease is head and neck squamous cell carcinoma.